Verastem, Inc. VSTM

VSTM Company Overview

Verastem, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing targeted therapies for patients with cancer. The company operates within the oncology and precision medicine sectors, with an emphasis on treatments designed to address RAS/MAPK pathway-driven cancers and other difficult-to-treat malignancies. Verastem’s strategy has historically centered on acquiring, developing, and advancing small-molecule therapeutics through clinical development and commercialization partnerships.

The company’s primary value drivers are its oncology drug candidates, licensing agreements, and collaboration arrangements tied to targeted cancer therapies. Verastem has evolved from an earlier focus on cancer stem cell biology into a broader precision oncology company pursuing combination therapies and pathway-targeted treatments. A major milestone in the company’s history was the commercialization of COPIKTRA (duvelisib), although strategic emphasis later shifted toward pipeline development programs, including RAF/MEK pathway-directed assets obtained through licensing and acquisition activity. Public disclosures and company filings indicate that Verastem’s operations remain heavily research and development-oriented, with revenue historically derived from product sales, licensing arrangements, and collaboration-related activities.